A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)
A rare aggressive variant of chondrosarcoma, characterized by a biphasic histologic pattern of small compact cells intermixed with islands of cartilaginous matrix. Mesenchymal chondrosarcomas have a predilection for flat bones; long tubular bones are rarely affected. They tend to occur in the younger age group and are highly metastatic. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1456)
A benign neoplasm derived from mesodermal cells that form cartilage. It may remain within the substance of a cartilage or bone (true chondroma or enchondroma) or may develop on the surface of a cartilage (ecchondroma or ecchondrosis). (Dorland, 27th ed; Stedman, 25th ed)
Tumors or cancer located in bone tissue or specific BONES.
Benign growths of cartilage in the metaphyses of several bones.
A malignant tumor arising from the embryonic remains of the notochord. It is also called chordocarcinoma, chordoepithelioma, and notochordoma. (Dorland, 27th ed)
A sarcoma, usually a liposarcoma or malignant fibrous histiocytoma, with an abundant component of myxoid tissue resembling primitive mesenchyme containing connective tissue mucin. (Stedman, 25th ed)
A non-vascular form of connective tissue composed of CHONDROCYTES embedded in a matrix that includes CHONDROITIN SULFATE and various types of FIBRILLAR COLLAGEN. There are three major types: HYALINE CARTILAGE; FIBROCARTILAGE; and ELASTIC CARTILAGE.
Neoplasms of the base of the skull specifically, differentiated from neoplasms of unspecified sites or bones of the skull (SKULL NEOPLASMS).
Hereditary disorder transmitted by an autosomal dominant gene and characterized by multiple exostoses (multiple osteochondromas) near the ends of long bones. The genetic abnormality results in a defect in the osteoclastic activity at the metaphyseal ends of the bone during the remodeling process in childhood or early adolescence. The metaphyses develop benign, bony outgrowths often capped by cartilage. A small number undergo neoplastic transformation.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
A set of twelve curved bones which connect to the vertebral column posteriorly, and terminate anteriorly as costal cartilage. Together, they form a protective cage around the internal thoracic organs.
Bones that constitute each half of the pelvic girdle in VERTEBRATES, formed by fusion of the ILIUM; ISCHIUM; and PUBIC BONE.
Enzymes which catalyze the elimination of glucuronate residues from chondroitin A,B, and C or which catalyze the hydrolysis of sulfate groups of the 2-acetamido-2-deoxy-D-galactose 6-sulfate units of chondroitin sulfate. EC 4.2.2.-.
Rare, benign, chronic, progressive metaplasia in which cartilage is formed in the synovial membranes of joints, tendon sheaths, or bursae. Some of the metaplastic foci can become detached producing loose bodies. When the loose bodies undergo secondary calcification, the condition is called synovial osteochondromatosis.
Glycoproteins which have a very high polysaccharide content.
A cartilage-capped benign tumor that often appears as a stalk on the surface of bone. It is probably a developmental malformation rather than a true neoplasm and is usually found in the metaphysis of the distal femur, proximal tibia, or proximal humerus. Osteochondroma is the most common of benign bone tumors.
Cancer or tumors of the MAXILLA or upper jaw.
NATIONAL LIBRARY OF MEDICINE service for health professionals and consumers. It links extensive information from the National Institutes of Health and other reviewed sources of information on specific diseases and conditions.
An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.
Microbodies which occur in animal and plant cells and in certain fungi and protozoa. They contain peroxidase, catalase, and allied enzymes. (From Singleton and Sainsbury, Dictionary of Microbiology and Molecular Biology, 2nd ed)
Value of all final goods and services produced in a country in one year.
A key enzyme in the glyoxylate cycle. It catalyzes the conversion of isocitrate to succinate and glyoxylate. EC 4.1.3.1.
An agency of the NATIONAL INSTITUTES OF HEALTH concerned with overall planning, promoting, and administering programs pertaining to advancement of medical and related sciences. Major activities of this institute include the collection, dissemination, and exchange of information important to the progress of medicine and health, research in medical informatics and support for medical library development.

Inhibitory effects of transforming growth factor-beta1 pretreatment on experimental pulmonary metastasis of MCS-1 Chinese hamster mesenchymal chondrosarcoma cells. (1/35)

Recent studies have suggested that transforming growth factor(TGF)-beta1 acts as a multifunctional regulator of cell growth, and also modifies tumor progression and metastasis. In the present study, we investigated the effects of TGF-beta1 on the proliferation and experimental pulmonary metastasis of MCS-1. MCS-1 are undifferentiated type cloned tumor cells established from a mesenchymal chondrosarcoma which spontaneously occurred in the soft tissue of a female Chinese hamster. MCS-1 cells were pretreated with TGF-beta1 (0, 0.05, 0.5, 2, 10 ng/ml) for 72 hours in a medium containing 1% fetal bovine serum, then tested for in vitro growth by the MTT method, in vivo growth by subcutaneous inoculation into athymic nude mice (1 x 10(6) cells/mouse) and experimental pulmonary metastasis by injection into the lateral tail vein of athymic nude mice (5 x 10(4) cells/mouse). TGF-beta1 significantly inhibited in vitro growth of MCS-1, depending on its concentrations, and also experimental metastasis with maximal inhibition at 0.5 or 2 ng/ml treatment compared to untreated controls. TGF-beta1, however, was ineffective for in vivo subcutaneous growth of MCS-1. These results indicated that TGF-beta1 might be an inhibitor of metastasis of mesenchymal chondrosarcomas including other types of non-epitherial cartilage or bone formation tumors.  (+info)

Cell differentiation and matrix gene expression in mesenchymal chondrosarcomas. (2/35)

Mesenchymal chondrosarcomas are small-cell malignancies named as chondrosarcomas due to the focal appearance of cartilage islands. In this study, the use of in situ detection techniques on a large series of mesenchymal chondrosarcoma specimens allowed the identification of tumor-cell differentiation pathways in these neoplasms. We were able to trace all steps of chondrogenesis within mesenchymal chondrosarcoma by using characteristic marker genes of chondrocytic development. Starting from undifferentiated cells, which were negative for vimentin and any other mesenchymal marker, a substantial portion of the cellular (undifferentiated) tumor areas showed a chondroprogenitor phenotype with an onset of expression of vimentin and collagen type IIA. Cells in the chondroid areas showed the full expression panel of mature chondrocytes including type X collagen indicating focal hypertrophic differentiation of the neoplastic chondrocytes. Finally, evidence was found for transdifferentiation of the neoplastic chondrocytes to osteoblast-like cells in areas of neoplastic bone formation. These results establish mesenchymal chondrosarcoma as the very neoplasm of differentiating premesenchymal chondroprogenitor cells. The potential of neoplastic bone formation in mesenchymal chondrosarcoma introduces a new concept of neoplastic (chondrocytic) osteogenesis in musculoskeletal malignant neoplasms, which qualifies the old dogma that neoplastic bone/osteoid formation automatically implies the diagnosis of osteosarcoma.  (+info)

Prostaglandin D synthase (beta-trace) in meningeal hemangiopericytoma. (3/35)

The level of prostaglandin D synthase (PGDS), a major protein constituent of cerebrospinal fluid (CSF), is altered in various brain diseases, including meningitis. However, its role in the brain remains unclear. PGDS is mainly synthesized in the arachnoid cells, the choroid plexus and oligodendrocytes in the central nervous system. Among brain tumors, meningiomas showed intense immunoreactivity to PGDS in the perinuclear region. Thus, PGDS has been considered a specific cell marker of meningioma. In this study, we examined 25 meningeal hemangiopericytomas (HPCs) and found that 16 of the tumors (64%) showed immunoreactivity for PGDS in the perinuclear region. For comparison, 15 meningiomas, 14 soft-tissue HPCs, 1 mesenchymal chondrosarcoma, 3 choroid plexus papillomas, and 7 oligodendrogliomas were also examined. Meningiomas showed positive immunoreactivity for PGDS in 13 cases (80%). Except for one case located at the sacrum, none of the other soft-tissue HPCs showed immunostaining for PGDS. Mesenchymal chondrosarcoma arises in the bones of the skull, and its histological pattern resembles that of HPC; however, it showed no immunoreactivity for PGDS. Neither choroid plexus papillomas nor oligodendrogliomas were immunopositive for PGDS. These findings suggest that meningeal HPCs may have a unique molecular phenotype that is distinct from that of the soft-tissue HPCs. The origin of meningeal HPCs may be more closely related to the arachnoid cells.  (+info)

Chondrosarcoma of bone: an oncological and functional follow-up study. (4/35)

We retrospectively analysed the course of 42 out of 45 patients suffering from different chondrosarcomas which were treated surgically. We found a prospective 5- and 10-year survival of 64% for both time intervals. Follow-up examination was possible in 21 of 45 patients. Most of them were staged as NED, one as AWD, and 8 of 45 were lost to follow-up. From 16 dead patients 12 died of the disease and 4 of unknown but not to tumor related reasons. Survival was depending significantly on the histopathological grade, and the stage according to Enneking's surgical staging system. Eleven out of forty-five patients developed metastases within a mean period of twelve months after surgery. The survival of these patients was significantly reduced. Patients with centrally located tumors exhibited a distinct but non-significant worse survival than those suffering from peripheral tumors. In 18% (8 of 45) recurrence of the tumor was evident within a mean period of 24 months (5-85). Functional evaluation was performed in 21 out of 28 alive patients. After a mean follow-up time of 72 months the mean score was 64% (23-100). Females exhibited a distinct but non-significant better result, the same was observed for peripheral locations compared to centrally located tumors. Regarding age, grade, and line of resection no tendency of any dependence was detected, but worst results were seen in those with a stage III tumor and dedifferentiated CS.  (+info)

Translocation der(13;21)(q10;q10) in skeletal and extraskeletal mesenchymal chondrosarcoma. (5/35)

Cytogenetic studies of mesenchymal chondrosarcoma are few and to date, no specific or recurrent aberrations have been found. In this investigation, the cytogenetic and molecular cytogenetic (spectral karyotypic and fluorescence in situ hybridization) findings for two mesenchymal chondrosarcomas, one arising skeletally and the other extraskeletally, are reported. An identical Robertsonian translocation involving chromosomes 13 and 21 [der(13;21)(q10;q10)] was detected in both cases, possibly representing a characteristic rearrangement for this histopathologic entity. Both cases also exhibited loss of all or a portion of chromosomes 8 and 20 and gain of all or a portion of chromosome 12. The observation of similar chromosomal abnormalities in both skeletal and extraskeletal mesenchymal chondrosarcoma supports a genetic as well as histopathologic relationship between these anatomically distinct neoplasms.  (+info)

Retroperitoneal extraskeletal mesenchymal chondrosarcoma in a dog. (6/35)

A young adult female Mastiff dog developed a large retroperitoneal mass, pleural effusion, and multiple pulmonary and pleural nodules. All masses were diagnosed as mesenchymal subtype chondrosarcomas, using histological and immunohistochemical criteria. Reports of canine extraskeletal mesenchymal chondrosarcomas (EMCs) are rare but involved animals less than 3 years of age in 60% of the cases. This is the first description of this type of tumor developing distant metastases. Evidence from this case and previous reports suggests that EMCs are associated with a poor prognosis.  (+info)

Mesenchymal chondrosarcoma originating from the femoral vein. (7/35)

Mesenchymal chondrosarcoma is a rare variant of chondrosarcomas characterized by a bimorphic pattern with areas of the undifferentiated malignant small cells and well differentiated cartilaginous islands.(1) It occurs most commonly in the bone but can also occur in the extraskeletal soft tissues, the brain, and the meninges. This type of tumor has also been described in the eyelids, parapharyngeal space, mediastinum, and the kidney.(1-5) An origin from the large vessels has not been reported in the medical literature. The authors report a case of mesenchymal chondrosarcoma originating from the femoral vein in a 28-year-old female patient, treated by the wide-margin resection.  (+info)

Cytopathology of mesenchymal chondrosarcomas: a report and comparison of four patients. (8/35)

BACKGROUND: Mesenchymal chondrosarcoma (MC) is an infrequent neoplasm, representing approximately 1% of all chondrosarcomas. Cytologic descriptions of MCs have been confined to rare case reports. In the current report, the authors describe their experience with the cytologic features of four MCs: two primary tumors and two metastatic lesions. METHODS: Four patients were diagnosed with MC at the authors' institution from 1994 to 2002. Three of four patients underwent fine-needle aspiration (FNA) biopsy as part of their diagnosis; in the fourth patient, imprint cytology was performed. Each tumor also received histologic confirmation. RESULTS: The patients studied included three females and one male. In three patients, the tumor presented initially as a soft tissue mass; whereas, in the remaining patient, the MC presented in the tibia. FNA results demonstrated small, oval-to-spindled cells with high nuclear-to-cytoplasmic ratios. Cells occurred singly and in clumps in a background of basophilic extracellular matrix. Histologic examination of each lesion demonstrated biphasic tumors, including focal areas of relatively mature cartilage formation as well as a small cell population. CONCLUSIONS: MC is a rare soft tissue tumor that occurs frequently in extraskeletal locations. FNA of these tumors can be diagnostic if the tumor is sampled appropriately and of critical features, such as the background extracellular matrix, are recognized. Given the propensity of these tumors to metastasize and the poor prognosis of patients with MC, early identification by FNA biopsy may allow earlier, more aggressive interventions.  (+info)

TY - JOUR. T1 - Intracranial extraskeletal mesenchymal chondrosarcoma. T2 - Case report. AU - Bingaman, Kimberly D.. AU - Alleyne, Cargill H.. AU - Olson, Jeffrey J.. PY - 2000/1. Y1 - 2000/1. N2 - OBJECTIVE AND IMPORTANCE: We present a patient with a dural-based intracranial extraskeletal mesenchymal chondrosarcoma, which was initially thought to be an atypical meningioma. This rare tumor should be considered in the differential diagnosis of young adults with an aggressive-appearing dural-based lesion. CLINICAL PRESENTATION: A 21-year-old woman reported a 3- week history of severe headaches and intermittent nausea and vomiting. Neurological examination revealed right optic nerve swelling. Magnetic resonance imaging demonstrated a large, intensely enhancing extra-axial mass, which appeared to originate from the right side of the falx cerebri with significant mass effect. A presumptive diagnosis of meningioma was made. INTERVENTION: The patient underwent preoperative embolization of the lesion ...
We should be careful in open reduction and internal fixation of fracture and also should consider in mind the diagnosis of pseudoaneurysm during plate removal,
We report on a patient who presented with swelling to the left side of the face accompanied by exophthalmos. Imaging studies revealed a large
However, differential diagnosis may be problematic at early stages with other ossified lesions of soft tissues: benign lesions such as myositis ossificans circumscripta (MOC), ossifying lipoma, soft tissue osteoma or chondroma, and ossifying fibromyxoid tumour, as well as malignant lesions such as classical high-grade ESOS, parosteal OS, mesenchymal chondrosarcoma, and synovial sarcoma. MOC is a benign heterotopic ossification of soft tissues characteristically associated with direct trauma [15]. It is one of the most important differential diagnoses, which was initially evoked - based on radiological and/or pathological aspects - in at least 3 out of the 7 reported cases of low-grade ESOS. Furthermore, a number of cases of ESOS presumably arising from MOC have been reported [16-19]. In MOC, both mature and immature bone is seen, as well as a prominent spindle cell and chondroid component, with a specific architecture described as the zonal phenomenon. This phenomenon refers to the presence of ...
Alvin Deguzman, long-time bassist of The Icarus Line, has died. He had been battling a rare form of cancer (mesenchymal chondrosarcoma), and finally lost the fight a few hours ago. As someone who has met him several times over the years, I am genuinely saddened by his passing. He was a cool dude. May you […]. ...
Ewing sarcoma shows considerable histologic overlap with other round cell tumors. NKX2-2, a homeodomain transcription factor involved in neuroendocrine/glial differentiation and a downstream target of EWSR1-FLI1, has been reported as an immunohistochemical marker for Ewing sarcoma. We assessed the specificity of NKX2-2 for Ewing sarcoma compared with other round cell malignant neoplasms and other soft tissue tumors with EWSR1 translocations. We evaluated whole-tissue sections from 270 cases: 40 Ewing sarcomas (4 with atypical/large cell features), 20 CIC-DUX4 sarcomas, 5 BCOR-CCNB3 sarcomas, 9 unclassified round cell sarcomas, 10 poorly differentiated synovial sarcomas, 10 lymphoblastic lymphomas, 10 alveolar rhabdomyosarcomas, 10 embryonal rhabdomyosarcomas, 10 Merkel cell carcinomas, 10 small cell carcinomas, 20 melanomas, 5 NUT midline carcinomas, 10 Wilms tumors, 10 neuroblastomas, 10 olfactory neuroblastomas, 12 mesenchymal chondrosarcomas, 10 angiomatoid fibrous histiocytomas, 10 clear ...
55 year old male with dedifferentiated chondrosarcoma and pathological fracture. Final Diagnosis: Left proximal femur and soft tissues, en bloc excision: Dedifferentiated chondrosarcoma High grade, grade 3/3 Maximum size 14.6 cm Tumor is ba...
Bone: Dedifferentiated chondrosarcoma, Authors: Andreas F Mavrogenis, Panayiotis J Papagelopoulos. Published in: Atlas Genet Cytogenet Oncol Haematol.
As for the genetics and causes of the cancer, it has been rather hard to find sources which can determine the cause of it, from the website…. The genetic changes specific to chondrosarcoma continue to be investigated extensively. Although studies have not yet established a specific or recurrent karyotypic feature for any of these tumors, different chondrosarcomas have demonstrated anomalies in several tumor suppressor genes, oncogenes, and transcription factors, including TP53, RAS, EXT1, EXT2, and Sox9. Available cytogenetic and comparative genomic hybridization (CGH) studies reveal changes in some chondrosarcomas, but fail to do so in others. These studies are thus far difficult to interpret.. Based on the available studies, it is likely that chondrosarcomas are generated by a coordinated, multi-step process involving primarily tumor suppressor genes. In fact, the complexity and variety of genetic changes seen in chondrosarcomas may indicate several distinct genetic pathways. Some of the ...
OBJECTIVE: To determine whether, in human fibroblasts and chondrosarcoma cells, the regulation of interleukins (IL)-6, 8, and 11 and matrix metalloproteinases (MMP)-1, 3, and 13, and their tissue inhibitor TIMP-1, depends on the transcription factor nuclear factor-kappaB (NF-kappaB). METHODS: Fibroblasts and chondrosarcoma cells were effectively infected with an adenovirus encoding human IkappaBalpha, and inhibition of NF-kappaB function was observed. The induction of MMP and IL-6, 8, and 11 by various stimuli was assessed by ELISA. RESULTS: The induction of IL-6 and IL-8 clearly depended on NF-kappaB in both fibroblasts and chondrosarcoma cells, irrespective of stimulus, but IkappaBalpha overexpression had little effect on IL-11. MMP-1, -3, and -13 were also inhibited, but TIMP-1 was unaffected. CONCLUSION: NF-kappaB appears to play an important and selective role in MMP induction in human fibroblasts and chondrosarcoma cells. This suggests there are NF-kappaB dependent mechanisms of cartilage
OBJECTIVE: To determine whether, in human fibroblasts and chondrosarcoma cells, the regulation of interleukins (IL)-6, 8, and 11 and matrix metalloproteinases (MMP)-1, 3, and 13, and their tissue inhibitor TIMP-1, depends on the transcription factor nuclear factor-kappaB (NF-kappaB). METHODS: Fibroblasts and chondrosarcoma cells were effectively infected with an adenovirus encoding human IkappaBalpha, and inhibition of NF-kappaB function was observed. The induction of MMP and IL-6, 8, and 11 by various stimuli was assessed by ELISA. RESULTS: The induction of IL-6 and IL-8 clearly depended on NF-kappaB in both fibroblasts and chondrosarcoma cells, irrespective of stimulus, but IkappaBalpha overexpression had little effect on IL-11. MMP-1, -3, and -13 were also inhibited, but TIMP-1 was unaffected. CONCLUSION: NF-kappaB appears to play an important and selective role in MMP induction in human fibroblasts and chondrosarcoma cells. This suggests there are NF-kappaB dependent mechanisms of cartilage ...
Chondrosarcomas are a primitive malignant tumor that derives from cartilage cells. It usually appears at the center of a bone segment, with no pre-existing lesions (central chondrosarcoma). It may also be secondary to a pre-existent condition suc...
Purpose: Chondrosarcomas are notoriously resistant to cytotoxic chemotherapeutic agents. We sought to identify critical signaling pathways that contribute to their survival and proliferation, and which may provide potential targets for rational therapeutic interventions. Experimental Design: Activation of receptor tyrosine kinases (RTKs) was surveyed using phospho-RTK arrays. S6 phosphorylation and NRAS mutational status were examined in chondrosarcoma primary tumor tissues. Small interfering RNA or small molecule inhibitors against RTKs or downstream signaling proteins were applied to chondrosarcoma cells and changes in biochemical signaling, cell cycle, and cell viability were determined. In vivo anti-tumor activity of BEZ235, a phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor, was evaluated in a chondrosarcoma xenograft model. Results: Several RTKs were identified as critical mediators of cell growth, but the RTK dependencies varied among cell lines. In ...
Chondrosarcoma can be of several types depending on the type of cells which are present in the tumor and how they appear microscopically. It is composed of transformed cells that produce cartilage. Radiograph of the head revealed lytic lesion with endosteal scalloping (A, arrow) and…, CT scan showed bone destruction of the skull (A) and matrix calcification (A,…, Transverse T1-weighted MRI (A) and its contrastenhanced image (C) showed a slightly low-signal…, Histopathological finding revealed proliferation of…, Histopathological finding revealed proliferation of the atypical chondrocytes (arrows) and cartilaginous component (C).…, NLM Clipboard, Search History, and several other advanced features are temporarily unavailable. Chondrosarcoma that occurs in a long bone of the leg, for example, is typically treated with the amputation of that leg. , Chondrosarcoma is a malignant tumor of the category known as sarcomas. Various types of cancer can affect the skeletal system, and an ...
Chondrosarcoma is a type of cancer that develops in cartilage cells. Cartilage is the specialized, gristly connective tissue that is present in adults and the tissue from which most bones develop. Cartilage plays an important role in the growth process. There are many different types of cartilage that are present throughout the body. Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur (thighbone), arm, pelvis, and knee. Although less frequent, other areas (such as the ribs) may be affected.. Chondrosarcoma is the second most common type of primary bone cancer. A primary bone cancer is one that originates from bone, as opposed to starting in another organ and then spreading to the bone. This type of cancer rarely affects individuals under age 20 and continues to rise until age 75. The incidence between males and females is equal.. ...
Chondrosarcoma is a type of cancer that develops in cartilage cells. Cartilage is the specialized, gristly connective tissue that is present in adults and the tissue from which most bones develop. Cartilage plays an important role in the growth process. There are many different types of cartilage that are present throughout the body. Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur (thighbone), arm, pelvis, and knee. Although less frequent, other areas (such as the ribs) may be affected.. Chondrosarcoma is the second most common type of primary bone cancer. A primary bone cancer is one that originates from bone, as opposed to starting in another organ and then spreading to the bone. This type of cancer rarely affects individuals under age 20 and continues to rise until age 75. The incidence between males and females is equal.. ...
TY - JOUR. T1 - Electrophoretic and serologic characterization of 56 kDa antigen (M56) with autologous serum derived from a chondrosarcoma patient. T2 - A shared antigen of immunoresponses in cancer and autoimmune diseases. AU - Fujiwara, Kazuo. AU - Udono, Heiichiro. AU - Kunisada, Toshiyuki. AU - Kawai, Akira. AU - Inoue, Hajime. AU - Takigawa, Masaharu. AU - Namba, Masayoshi. AU - Nakayama, Eiichi. PY - 1999. Y1 - 1999. N2 - We investigated whether antibodies specific to autologous cancer cells are produced in the peripheral blood of patients with chondrosarcoma. There have been few reports on the investigation of the immune responses, such as autologous antibody production, to chondrosarcoma. Here, tumor-associated antigens were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and detected by immunoenzymatic amplification. A 56 kDa molecule (M56) was detected in the serum from patients peripheral blood. M56 is ubiquitously expressed in various kinds of ...
Chondrosarcomas are characteristic for their slow but progressive invasion of the surrounding tissues. These malignant, cancerous tumors originate in the cartilage, the connective tissue between bones.
Clear-cell chondrosarcoma is a variant of chondrosarcoma which is characterized by a typical histomorphology and a very slow rate of growth. A case is presented in which the tumor was located in the maxilla. show less ...
Learn about the rare cancer Chondrosarcoma, its symptoms, causes, diagnosis methods, and treatment options available to overcome the problem.
Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur, arm, pelvis, knee, and spine.
Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur, arm, pelvis, knee, and spine.
Chondrosarcoma treatments include chemotherapy, radiation therapy, targeted therapies, and surgery, to remove the mass and reduce the likelihood of return.
Kevin B. Jones, MD of University of Utah - Huntsman Cancer Institute receives grant for Polarity and Ploidy in Peripheral Chondrosarcoma research.
Supplementary Material for: MiR-129-5p Inhibits Proliferation and Invasion of Chondrosarcoma Cells by Regulating SOX4/Wnt/β-Catenin Signaling Pathway
Learn more about Chondrosarcoma at Coliseum Health System DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision .....
Chondrosarcoma is a rare type of cancer that usually begins in the bones, but can sometimes occur in the soft tissue near bones. The most common locations for chondrosarcoma tumors are in the pelvis, hip and shoulder. More rarely, the base of the skull is affected. ...
No. of Printed Pages : 3 MCA (Revised) MCS-012 Term-End Examination tr) June, 2011 cNI 0 ,--. MCS-012 : COMPUTER ORGANISATION & ASSEMBLY LANGUAGE
AIMS: Neuroblastoma shows considerable histological overlap with other small round blue cell tumours. PHOX2B, a transcription factor that is essential for autonomic nervous system development, has been reported as an immunohistochemical marker for neuroblastoma. The aim of this study was to validate the specificity and diagnostic utility of PHOX2B for peripheral neuroblastic tumours. METHODS AND RESULTS: We evaluated 240 cases (133 in whole-tissue sections; 107 in tissue microarrays), including 76 peripheral neuroblastic tumours (median age 2 years; including four adults) and 164 other tumours: 44 Wilms tumours; 20 Ewing sarcomas; 10 each of CIC-rearranged round cell sarcomas, poorly differentiated synovial sarcomas, lymphoblastic lymphomas, alveolar rhabdomyosarcomas, embryonal rhabdomyosarcomas, mesenchymal chondrosarcomas, Merkel cell carcinomas, olfactory neuroblastomas, and melanomas; and five each of NUT midline carcinomas and desmoplastic small round cell tumours ...
Chondrosarcoma is a type of highly malignant tumor with a potent capacity to invade locally and cause distant metastasis. Chondrosarcoma shows a predilection for metastasis to the lungs. Interleukin-8 (IL-8), a chemokine with a defining CXC amino acid motif, is known to possess tumorigenic and proangiogenic properties. Over-expression of IL-8 has been detected in many human tumors. However, the effects of IL-8 in migration and integrin expression in chondrosarcoma cells are largely unknown. In this study, we found that IL-8 increased the migration and the expression of αvβ3 integrin in human chondrosarcoma cells. Activations of phosphatidylinositol 3-kinase (PI3K), Akt, and AP-1 pathways after IL-8 treatment were demonstrated, and IL-8-induced expression of integrin and migration activity was inhibited by the specific inhibitor and mutant of PI3K, Akt, and AP-1 cascades. Taken together, our results indicated that IL-8 enhances the migration of chondrosarcoma cells by increasing αvβ3 integrin ...
Chondrosarcomas are malignant cartilage tumors that do not respond to traditional chemotherapy or radiation. The 5-year survival rate of histologic grade III chondrosarcoma is less than 30%. To achieve a greater understanding of chondrosarcoma tumorigenesis, a model for human chondrosarcoma has been established in a rat system. The model, known as the Swarm rat chondrosarcoma (SRC), resembles human chondrosarcoma and provides a system to study tumor growth and progression. Here we examined the influence of the tumor microenvironment and the impact of genome-wide hypomethylation on the behavior of SRC tumors, two factors known to contribute fundamentally to the development and progression of solid tumors. Previous studies with SRC revealed that tumor microenvironment can significantly influence chondrosarcoma malignancy, but the underlying biologic mechanisms have not been defined. To address this issue we carried out epigenetic and gene expression studies on the SRC tumors that were initiated at
TY - JOUR. T1 - Chondrosarcoma. T2 - Its treatment by radiation, hyperthermia and bleomycin. AU - Okuyama, S.. AU - Itoh, M.. AU - Tanaka, K.. AU - Matsuzawa, T.. PY - 1978/12/1. Y1 - 1978/12/1. N2 - A case of chondrosarcoma of the mandible of surgical failure was treated by radiation, hyperthermia, and bleomycin. The treatment resulted in selective necrosis of the tumor. This can be designated as perpetuation principle of radiothermotherapy because bleomycin may inhibit the repair processes of heat and radiation damage. This principle appears to offer selectivity of the therapeutic effects, to open a way to treatment of those radioresistant selectivity of the therapeutic effects, open a way to treatment of those radioresistant malignancies, and to enhance curability of various medium-sensitive tumors. Additionally, a course of large-dose glutathione infusion was confirmed to promptly alleviate radiation dermatitis and mucositis.. AB - A case of chondrosarcoma of the mandible of surgical failure ...
Imaging studies - including radiographs (x-rays), computerized tomography (CT), and magnetic resonance imaging (MRI) - are often used to make a presumptive diagnosis of chondrosarcoma. However, a definitive diagnosis depends on the identification of malignant cancer cells producing cartilage in a biopsy specimen that has been examined by a pathologist. In a few cases, usually of highly anaplastic tumors, immunohistochemistry (IHC)is required.. There are no blood tests currently available to enable an oncologist to render a diagnosis of chondrosarcoma. The most characteristic imaging findings are usually obtained with CT.. Nearly all chondrosarcoma patients appear to be in good health. Often, patients are not aware of the growing tumor until there is a noticeable lump or pain. Earlier diagnosis is generally accidental, when a patient undergoes testing for another problem and physicians discover the cancer. Occasionally the first symptom will be a broken bone at the cancerous site. Any broken ...
Get information, facts, and pictures about Chondrosarcoma at Encyclopedia.com. Make research projects and school reports about Chondrosarcoma easy with credible articles from our FREE, online encyclopedia and dictionary.
We report an unusual case of a young woman with chondrosarcoma affecting the greater cornu of the hyoid bone. Only a handful of reports of primary chondrosarcoma involving the hyoid exist in the world literature. The case described presented as a swe
TY - JOUR. T1 - An extraskeletal chondrosarcoma of the maxilla. A case report. AU - Nishioka, Gary. AU - Holt, G. Richard. AU - Aufdemorte, Thomas B.. AU - Triplett, Robert G.. PY - 1995/2. Y1 - 1995/2. UR - http://www.scopus.com/inward/record.url?scp=0028858834&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0028858834&partnerID=8YFLogxK. U2 - 10.1016/0278-2391(95)90401-8. DO - 10.1016/0278-2391(95)90401-8. M3 - Article. C2 - 7830187. AN - SCOPUS:0028858834. VL - 53. SP - 193. EP - 195. JO - Journal of Oral and Maxillofacial Surgery. JF - Journal of Oral and Maxillofacial Surgery. SN - 0278-2391. IS - 2. ER - ...
Although a rare entity, chondrosarcoma is the most common malignant tumor of the chest wall. Most patients present with an enlarging, painful anterior chest wall mass arising from the costochondrosternal junction. CT scan with intravenous contrast is the gold standard radiographic study for diagnosis and operative planning. Contrary to previous dictum, resection may be performed in an appropriate surgical candidate based on imaging characteristics or image-guided percutaneous biopsy results; incisional biopsy is rarely required. The keys to successful treatment are early recognition and radical excision with adequate margins, as chondrosarcoma is relatively resistant to radiotherapy and conventional cytotoxic chemotherapy. Overall survival is excellent in most surgical series from experienced centers. Complete excision with widely negative microscopic margins at the initial operation is of the utmost importance, as local recurrence portends systemic metastasis and eventual tumor-related mortality. This
A chondrosarcoma in the anterior mediastinum is a rare finding with a relatively good prognosis. We describe a case of a 75-year-old man with a 2-year history of neck discomfort and weight loss. Imaging showed a homogenous tumor with a minor compression on the anterior part of the heart. It had close relation to the ribs, no surrounding fat, and a thymoma was suspected. Biopsy prior to surgery was impossible due to the location of the tumor. Unfortunately, final pathology from the surgical specimen revealed a chondrosarcoma. ...
Depending on the type of chondrosarcoma, it may spread slowly or very rapidly. Its presently unknown what causes this type of cancer. This is partially because it is so unusual that there are not a lot of cases to study. A higher incidence of nasal CSAs among cats living in urban areas may indicate a link to air pollution. The type affecting bones has been found to contain viruses in the cells of the tumor, suggesting a viral connection. Some bone tumors develop on the site of a previous fracture, which may mean theres a link with the bodys cells that heal a broken bone. But its believed that several factors combine with each unique cats physiology to cause the cells to become cancerous ...
A chondrosarcoma is one of several types of laryngeal tumors that can effect the larynx and trachea of a dog. This is a relatively rare and fast spreading tumor that originates in the cartilage, a connective collagenous tissue that is found throughout the body.
The following are treatment options for all stages of chondrosarcoma. The types of treatments given are based on the unique needs of the person with cancer.
Gentaur molecular products has all kinds of products like :search , US Biomax \ Osteosarcoma and chondrosarcoma tissue array, with stage, grade and TNM data, 80 cases_80 cores, replacing OS801 and BC26111; ihc Anti-Actin confirmed \ OS802 for more molecular products just contact us
Pain is the usual presenting symptom; alternatively the tumour may be found incidentally on imaging. Signs are localise to the involved bone. Imaging appearances are difficult as most chondrosarcomas resemble benign chondroma. The most common features are of central lucency with expansion and thickening of the overlying cortex.. ...
These deficits are summarized in Display 10-17, the lesions are charac- terized by a bimorphic pattern that is composed of highly undifferentiated small round cells and islands of well- differentiated hyaline cartilage. Judicial procedures It is exaemn established that governing body disciplinary procedures Propranolo subject to the propranтlol of natural justice. L.
CAMMC of the larynx are rare tumors but have a better prognosis than their axial counterparts (mean, 6 mo). Initial voice-sparing surgery can be followed with more aggressive surgery if recurrences develop.
The primary purpose of this study is to determine if the administration of a higher dose would decrease the chance of tumor recurrence, compared to the risk of tumor recurrence with a lower dose. Most of the treatment will be given protons, but participants may receive a small portion of treatment with x-rays, because less radiation is given to the skin with x-rays. This study uses two slightly different doses of radiation It is not clear at this time which of the dose levels is better ...
The primary purpose of this study is to determine if the administration of a higher dose would decrease the chance of tumor recurrence, compared to the risk of tumor recurrence with a lower dose. Most of the treatment will be given protons, but participants may receive a small portion of treatment with x-rays, because less radiation is given to the skin with x-rays. This study uses two slightly different doses of radiation It is not clear at this time which of the dose levels is better ...
Axial T2 weighted MR image again demonstrates the mass with typical high signal lobular growth pattern of cartilage representing cap.
When I was diagnosed with ovarian cancer, the first reaction was of course panic, and then I Packed up and started to look for information on the Internet and on the forums. Im still grateful to all those people who write reviews about their appeal to different professionals - I this information helped to survive. That is why I write about how I got to Israel, and how I was able to overcome the disease.The purpose of my search information on the Internet to understand where and how to treat ovarian cancer, what are my prospects in General? The important thing is that I knew we must act quickly. Of course, I wanted to go to a top specialist because of the ability to experiment just wasnt there.I immediately realized that I wanted to be treated in Israel, as there is a percentage of cure from cancer is very high, including ovarian cancer. This treatment is cheaper than, say, the USA or Germany, for me it was also an important argument. I only had to choose the doctor. About Professor Moshe Inbar ...
The actuarial 5- and 10-year survival rates after GKS were 80 and 53%, respectively. The actuarial 5- and 10-year local tumor control (LTC) rates after single or multiple GKS sessions were 76 and 67%, respectively. All patients with low-grade chondrosarcomas achieved good LTC. A tumor volume of less than 20 ml significantly affected the high rate of LTC (p = 0.0182). No patient had adverse radiation effects, other than one in whom facial numbness worsened despite successful tumor control. ...
The actuarial 5- and 10-year survival rates after GKS were 80 and 53%, respectively. The actuarial 5- and 10-year local tumor control (LTC) rates after single or multiple GKS sessions were 76 and 67%, respectively. All patients with low-grade chondrosarcomas achieved good LTC. A tumor volume of less than 20 ml significantly affected the high rate of LTC (p = 0.0182). No patient had adverse radiation effects, other than one in whom facial numbness worsened despite successful tumor control. ...
Dr. Post called with my biopsy results and told me I have a very rare form of bone cancer called chondrosarcoma. I am very blessed because it is Grade One meaning, its treatable through surgery and the percentage of recurrence is very low. Thank you Jesus! Chemo and radiation wont help my type of cancer so it…
Clear cell Clear cell chondrosarcomas are rare, slow-growing, and seldom spread. Mesenchymal Mesenchymal chondrosarcomas can ... "Mesenchymal chondrosarcoma , Radiology Reference Article , Radiopaedia.org". Radiopaedia. Müller S, Söder S, Oliveira AM, ... Most chondrosarcomas develop in the pelvis, legs or arms. Benign counterparts are known as enchondromas. Chondrosarcomas are ... "Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton". Mod ...
IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal ... CT scan and gross pathology of a chondrosarcoma 2012-12-18 "Chondrosarcoma". The Lecturio Medical Concept Library. Retrieved 8 ... A chondrosarcoma is a member of a category of tumors of bone and soft tissue known as sarcomas. About 30% of bone sarcomas are ... Nearly all chondrosarcoma patients appear to be in good health. Often, patients are not aware of the growing tumor until there ...
... in mesenchymal chondrosarcoma". PLOS ONE. 7 (11): e49705. Bibcode:2012PLoSO...749705N. doi:10.1371/journal.pone.0049705. PMC ...
Miller was diagnosed with mesenchymal chondrosarcoma, a form of bone cancer, in 2008, the same year that With Arrows, With ...
... (EMC) is a rare low-grade malignant mesenchymal neoplasm of the soft tissues, that differs ... "Myxoid Chondrosarcoma - an overview , ScienceDirect Topics". www.sciencedirect.com. Retrieved 2019-02-04. "TAF15 TATA-box ... when they discussed the different species of extraskeletal chondrosarcoma, but EMC concept was firstly proposed in 1972 by ... Yang, Lei; Qin, Genggeng; Xu, Rong; Wang, Ruoning; Zhang, Ling (2018). "Extraskeletal Myxoid Chondrosarcoma: A Comparative ...
Expression of epigenetic modifiers such as that of the BMI1 component of the PRC1 complex is deregulated in chondrosarcoma, ... Sarcomas comprise a large number of rare, histogenetically heterogeneous mesenchymal tumors that, for example, include ... Similarly, expression of another epigenetic modifier, the LSD1 histone demethylase, is increased in chondrosarcoma, Ewing's ... Bennani-Baiti IM (December 2011). "Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis ...
... been mistaken for rare types of other sarcomas that sometimes have epithelioid features such as mesenchymal chondrosarcomas, ... Du W, Liu X, Yang M, Wang W, Sun J (2021). "The Regulatory Role of PRRX1 in Cancer Epithelial-Mesenchymal Transition". ... the PRRX1 gene product protein regulates epithelial-mesenchymal transition and may be involved in the development of various ...
... chondrosarcoma MeSH C04.557.450.565.280.280 - chondrosarcoma, mesenchymal MeSH C04.557.450.565.380 - giant cell tumors MeSH ... chondrosarcoma MeSH C04.557.450.795.300.280 - chondrosarcoma, mesenchymal MeSH C04.557.450.795.350 - fibrosarcoma MeSH C04.557. ...
... the more common fetal and embryonal types do not Merkel cell carcinoma Mesenchymal chondrosarcoma Endometrial stromal ...
Ewing sarcoma 7.2 Chondro-osseous tumours 7.2.1 Chondrogenic tumours 7.2.1.1 Mesenchymal chondrosarcoma 7.2.1.2 Chondrosarcoma ... 7.1.3 Skeletal muscle tumours 7.1.3.1 Rhabdomyosarcoma 7.1.4 Uncertain differentiation 7.1.4.1 Intracranial mesenchymal tumour ...
Myxoid chondrosarcoma M9240/3 Mesenchymal chondrosarcoma M9241/0 Chondromyxoid fibroma M9242/3 Clear cell chondrosarcoma M9243/ ... NOS Mixed mesenchymal tumor M8990/3 Mesenchymoma, malignant Mixed mesenchymal sarcoma M8991/3 Embryonal sarcoma M9000/0 Brenner ... M9221/0 Juxtacortical chondroma Periosteal chondroma M9221/3 Juxtacortical chondrosarcoma Periosteal chondrosarcoma M9230/0 ... 3 Dedifferentiated chondrosarcoma M9250/1 giant cell tumor of bone, NOS Osteoclastoma, NOS M9250/3 Giant cell tumor of bone, ...
Yang J, Ren Z, Du X, Hao M, Zhou W (27 October 2014). "The role of mesenchymal stem/progenitor cells in sarcoma: update and ... Some sarcomas, such as leiomyosarcoma, chondrosarcoma, and gastrointestinal stromal tumor (GIST), are more common in adults ... A sarcoma is a malignant tumor, a type of cancer that arises from transformed cells of mesenchymal (connective tissue) origin. ... These subtypes are as follows: Osteosarcoma Chondrosarcoma Poorly differentiated round/spindle cell tumors (includes Ewing ...
Mesenchymal chondrosarcoma - Metaphysis - Metatarsophalangeal joint sprain - Microfracture surgery - Milch classification - ... Myxoid chondrosarcoma National hip fracture database - Neer classification - Neer impingement sign - Neer's prosthesis - ... Chondrosarcoma - Chopart's fracture-dislocation - Clarke's test - Clavicle fracture - Clay-shoveler fracture - Cleidocranial ...
Chondrosarcoma is a more malignant type of tumor, but most are low grade tumors and often appear in the axial skeletal region. ... As suggested in the name, mesenchymal progenitors originate from the mesoderm. These cells, when forming from the mesoderm, ... Day, Timothy F.; Guo, Xizhi; Garrett-Beal, Lisa; Yang, Yingzi (2005). "Wnt/β-Catenin Signaling in Mesenchymal Progenitors ... Chondroblasts, or perichondrial cells, is the name given to mesenchymal progenitor cells in situ which, from endochondral ...
However, the gene has been found to be highly expressed in chondrosarcoma. Chondrosarcoma is the cancer of the cells that ... especially mesenchymal cells. The vimentin protein is also responsible for maintaining cell shape, integrity of the cytoplasm, ... Therefore, there seems to be an association between IFFO1's filamentous characteristic and chondrosarcoma. One nuclear export ...
Failure to stop growth can be indicative of transformation to malignant chondrosarcoma. Treatment is not indicated unless ... characteristics of the neoplastic cells causing giant cell tumors of bone indicate an origin of pluripotent mesenchymal stem ...
... such as chondrosarcoma). There is a variety of chemotherapy treatment protocols for bone tumors. The protocol with the best- ... other mesenchymal tumors of bone, and hematopoietic neoplasms of bone. Bone tumors may be classified as "primary tumors", which ... chondrosarcoma, Ewing's sarcoma, fibrosarcoma, and other types. While malignant fibrous histiocytoma (MFH) - now generally ...
The metaphysis contains a diverse population of cells including mesenchymal stem cells, which give rise to bone and fat cells, ... Metaphyseal tumors or lesions include osteosarcoma, chondrosarcoma, fibrosarcoma, osteoblastoma, enchondroma, fibrous dysplasia ...
"Intracranial mesenchymal tumor with FET-CREB fusion-A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal ... Extraskeletal myxoid chondrosarcoma: These tumors' neoplastic cells express the EWSR1-NR4A3 fusion gene in most cases or the ... Intracranial mesenchymal tumors with FET‐CREB fusions: These tumors are suggested to be a variant of the angiomatoid fibrous ...
... mesenchymal cells. There are some who think it is a myoepithelial tumor type. Derived from ectomesenchymal cells migrating from ... extraskeletal myxoid chondrosarcoma, focal oral mucinosis, and an ossifying fibromyxoid tumor of soft parts. Exceedingly rare, ...
Chondrosarcoma Ewing's sarcoma Malignant fibrous histiocytoma of bone/osteosarcoma Osteosarcoma Rhabdomyosarcoma Leiomyosarcoma ... each of which develop from cells originating in mesenchymal cells outside of the bone marrow. Lymphoma and leukemia: These two ...
Romeo et al have observed chondroblastoma neoplasms to be composed of mesenchymal cells that have completed normal ... clear cell chondrosarcomas, and enchondromas (this list is not exhaustive). Chondroblastoma has not been known to spontaneously ... These findings suggest that chondroblastoma is derived from a mesenchymal cell undergoing chondrogenesis via active growth- ... any definitive determinations regarding the origin of this neoplasm are not possible because of the plasticity of mesenchymal ...
LGFMS can be difficult to distinguish from other mesenchymal tumors, particularly from sclerosing epithelioid fibrosarcoma (SEF ... extraskeletal myxoid chondrosarcoma, synovial sarcomas that have a prominent myxoid background, or myxoid liposarcoma. However ...
GDF5 Chondrosarcoma; 215300; EXT1 Chondrosarcoma, extraskeletal myxoid; 612237; TAF15 Chondrosarcoma, extraskeletal myxoid; ... RSPO4 Anterior segment mesenchymal dysgenesis; 107250; FOXE3 Anterior segment mesenchymal dysgenesis; 107250; PITX3 ... 612237; TFG Chondrosarcoma, extraskeletal myxoid; 612237; CSMF Chorea, hereditary benign; 118700; NKX2-1 Choreoacanthocytosis; ...
Specifically, it is an aggressive malignant neoplasm that arises from primitive transformed cells of mesenchymal origin (and ... Differential diagnosis of the osteosarcoma of the skull in particular includes, among others, chondrosarcoma and the ...
... chondrosarcoma - chordoma - chorioallantoic membrane - choriocarcinoma - choroid plexus tumor - CHPP - chronic granulocytic ... mesenchymal - mesenteric membrane - mesna - mesonephroma - mesothelioma - metaplasia - metaplastic carcinoma - metastasectomy ...
Volckaert T, De Langhe SP (March 2015). "Wnt and FGF mediated epithelial-mesenchymal crosstalk during lung development". ... chondrosarcoma, fibrosarcoma, liposarcoma, rhabdomyosarcoma and synovial sarcoma) and there is compelling evidence that it ...
... (RMS) is a highly aggressive form of cancer that develops from mesenchymal cells that have failed to fully ... chondrosarcoma, or angiosarcoma". The American Journal of Surgical Pathology. 26 (9): 1175-1183. doi:10.1097/00000478-200209000 ...
Connect people with Mesenchymal Chondrosarcoma close to you and help each other. , Diseasemaps ...
Videos for cancer patients made by cancer patients. Views and experiences that the doctors cant tell you.
Mesenchymal stem cells preconditioned with myeloma cells from high-risk patients support the growth of myeloma cells from low- ... Mesenchymal stem cells preconditioned with myeloma cells from high-risk patients support the growth of myeloma cells from low- ... Signatures of mesenchymal cell lineages and microenvironment factors are dysregulated in high risk myeloma. Blood. 2016;128(22 ... Signatures of mesenchymal cell lineages and microenvironment factors are dysregulated in high risk myeloma. Blood. 2016;128(22 ...
Mesenchymal chondrosarcoma * Extraskeletal osteosarcoma Gastrointestinal stromal tumors. Gastrointestinal stromal tumors (GISTs ...
Coexistence of Extraskeletal Mesenchymal Chondrosarcoma and Isolated Hemihyperplasia: A Case Report.. Arthroscopic fixation of ... Congenital sacral mesenchymal chondrosarcoma in a neonate: a case report and review of literature.. ... Primary retroperitoneal extraskeletal mesenchymal chondrosarcoma involving the vena cava: A case report. ... Primary retroperitoneal extraskeletal mesenchymal chondrosarcoma involving the vena cava: A case report.. ...
Mesenchymal chondrosarcomas (MCs) are infrequent, slowâ  growing malignant tumors of head and neck region affecting both bone ... Mesenchymal Chondrosarcoma of Posterior Maxilla: Report of a Case with Brief Literature Review. Author(s): Kumar MCD, Suresh KV ... Mesenchymal chondrosarcomas (MCs) are infrequent, slowâ growing malignant tumors of head and neck region affecting both bone ... It represents approximately 1% of all chondrosarcomas. They usually occur in the middle aged individuals, but rarely seen in ...
Chondrosarcoma is a collective term for a group of tumors that consist predominantly of cartilage and that range from low-grade ... Mesenchymal chondrosarcoma. The 5-year survival rate for mesenchymal chondrosarcoma is less than 50%, with an overall 10-year ... Fewer than 2% of all chondrosarcomas are mesenchymal chondrosarcomas. The maxilla and the mandible are the most common sites of ... Chondrosarcoma is a tumor of mesenchymal origin that predominantly is made of cartilage; it is the second most common primary ...
A mesenchymal chondrosarcoma of the right tibia in a young man requires disarticulation of the right knee: A case study Youness ... Chondrosarcoma is a malignant tumor occupying the 2nd position in terms of frequency, all ages combined, after osteosarcoma [1 ...
... extraskeletal mesenchymal chondrosarcoma; extraskeletal myxoid chondrosarcoma; extraskeletal osteosarcoma; infantile ...
Dedifferentiated Chondrosarcoma with a High-Grade Mesenchymal Component Mimicking a Gastrointestinal Stromal Tumor (Articles) ...
Chondrosarcoma including spindle cell and myxoid chondrosarcoma: mesenchymal chondrosarcoma. Bone tumors: diagnosis, treatment ... Chondrosarcoma. Different variants of chondrosarcoma. Revista Espa ola de Patolog a 2006; 39(2): 69-79. ... Extraskeletal myxoid chondrosarcoma. Enzinger and Weiss s Soft Tissue Tumors. St Louis: Mosby; 2001: 1368-79. ... Varma DGK, Ayala AG, Carrasco CH, Shan-Qun G, Kumar R, Edeiken J. Chondrosarcoma: MR Imaging with pathologic. RadioGraphics ...
Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal ... Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy.. Am J Clin Oncol. 1995; 18: 161-163. View in ... Activity of sunitinib in extraskeletal myxoid chondrosarcoma.. Eur J Cancer. 2014; 50: 1657-1664. View in Article *Scopus (50) ... Extraskeletal myxoid chondrosarcoma.. in: Fletcher CD Bridge JA Hogendoorn PCW Mertens F WHO classification of tumours of soft ...
... in Mesenchymal Chondrosarcoma. KB Nyquist, I Panagopoulos, J Thorsen, L Haugom, L Gorunova, ... ...
Primary intraspinal dura mesenchymal chondrosarcoma. Lee, S. T., Lui, T. N. & Tsai, M. D., 1989, 於: Surgical Neurology. 31, 1, ...
Mesenchymal tumor, malignant, Malignant mesenchymal tumor, Malignant mesenchymal tumour, Malignant tumor of soft tissue, ... Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.. Definition (NCI_CDISC). A malignant ... A malignant mesenchymal tumor for which a distinct line of differentiation cannot be determined. This term may be used for ... A malignant mesenchymal neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive ...
Ten-year survival of a rare malignancy called mesenchymal chondrosarcoma has been reported to be as low as 20 percent. But a ... Ten-year survival of a rare malignancy called mesenchymal chondrosarcoma has been reported to be as low as 20 percent. But a ...
IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal ... including brain tumors called gliomas and bone tumors known as chondrosarcomas. Like the genetic changes that cause CN-AML ( ...
Extraskeletal Mesenchymal Chondrosarcoma of Oral Cavity. Grandhi A, Wiston R, Reich R, Freedman P. Residents & Fellows Research ... Extraskeletal Mesenchymal Chondrosarcoma of Oral Cavity. Grandhi A, Wiston R, Reich R, Freedman P. American Academy of Oral & ...
Morphologic diagnosis: aortic chondrosarcoma.. Case summary: primary aortic chondrosarcoma affecting cranial and caudal ( ... CSA generally consists of lobules of mesenchymal cells producing variable quantities of disorganized hyaline cartilage or ... Dedifferentiated chondrosarcoma in the dog and cat: a case series and review of the literature. J Am Anim Hosp Assoc. 2018;54: ... Dedifferentiated chondrosarcoma in the dog and cat: a case series and review of the literature. J Am Anim Hosp Assoc. 2018;54: ...
... data presented in this proposal demonstrates that IDH mutations impair the differentiation of untransformed mesenchymal ... Deciphering the effects of IDH mutations on chromatin and differentiation in chondrosarcoma. Juan Manuel Schvartzman, MD, PhD, ... IDH mutations are seen in 50% of chondrosarcomas, which represent approximately 25% of malignant bone neoplasms. The oncogenic ... and on-treatment samples of locally advanced IDH-mutant chondrosarcoma patients treated with an IDH1-mutant inhibitor to study ...
Novel low-grade renal spindle cell neoplasm with HEY1::NCOA2 fusion that is distinct from mesenchymal chondrosarcoma. Miller, ...
Falcine mesenchymal chondrosarcoma: A case report. Dr. Ghassen Gader. Ver E-Poster ...
Differentiation of human mesenchymal stem cells in vitroresulted in induction of NFATp mRNA under chondrogenic conditions but ...
Chondrosarcomas, Mesenchymal. Mesenchymal Chondrosarcoma. Mesenchymal Chondrosarcomas. Tree number(s):. C04.557.450.565.280.280 ... Chondrosarcoma, Mesenchymal - Preferred Concept UI. M0027440. Scope note. A rare aggressive variant of chondrosarcoma, ... Mesenchymal chondrosarcomas have a predilection for flat bones; long tubular bones are rarely affected. They tend to occur in ... Mesenchymal chondrosarcomas have a predilection for flat bones; long tubular bones are rarely affected. They tend to occur in ...
Mesenchymal chondrosarcoma (morphologic abnormality). Code System Preferred Concept Name. Mesenchymal chondrosarcoma ( ...
A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a ... ... 2013). Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl- ... A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a ... Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen ...
  • Chondrosarcoma is a malignant tumor occupying the 2nd position in terms of frequency, all ages combined, after osteosarcoma [1]. (peertechzpublications.com)
  • With patients who present with locally advanced or metastatic chondrosarcoma, chordoma, or osteosarcoma, physicians should discuss the options surrounding deep-sequencing genomic tests, which may identify mutations that may be responsive to specific therapies and thus may guide referral to clinical trials. (medscape.com)
  • Chondrosarcoma (Chs) is the third most frequent primary malignant tumour of bone exceeded only by myeloma and osteosarcoma. (biomedcentral.com)
  • Chondrosarcoma is a collective term for a group of tumors that consist predominantly of cartilage and that range from low-grade tumors with low metastatic potential to high-grade, aggressive tumors characterized by early metastasis. (medscape.com)
  • Mesenchymal chondrosarcomas (MCs) are infrequent, slowâ growing malignant tumors of head and neck region affecting both bone and soft tissues. (amhsr.org)
  • Somatic mutations in the IDH1 gene have been associated with several other forms of cancer, including brain tumors called gliomas and bone tumors known as chondrosarcomas. (medlineplus.gov)
  • These proposed studies will lead to an enhanced understanding of how metabolic enzyme mutations impair differentiation in chondrosarcomas and unlock the potential of differentiation therapy in solid tumors, a long-sought hurdle of cancer treatment. (curesarcoma.org)
  • Chondrosarcoma is a member of this group, as this is the tumors of cartilage producing cells. (alwaysayurveda.net)
  • Chondrosarcomas are a group of tumors with highly diverse features and behavior patterns, ranging from slow-growing nonmetastasizing lesions to highly aggressive metastasizing sarcomas. (medscape.com)
  • Primary (conventional) chondrosarcomas (85-90%) occur in preexisting normal bone, whereas secondary tumors occur in preexisting enchondromas and osteochondromas. (medscape.com)
  • The imaging appearances of chondrosarcoma may overlap with those of other lesions, especially other cartilaginous tumors such as enchondroma. (medscape.com)
  • Chondrosarcomas are malignant cartilage-forming bone tumors, which are intrinsically resistant to chemo- and radiotherapy, leaving surgical removal as the only curative treatment option. (csfshayna.org)
  • Sensitivity to YM155, a survivin inhibitor currently in phase I/II clinical trial for other tumors, was examined in 10 chondrosarcoma cell lines using viability assay, apoptosis assay and cell-cycle analysis. (csfshayna.org)
  • Chondrosarcoma is a malignant cartilage-forming tumor accounting for 20% of all malignant bone tumors. (csfshayna.org)
  • patients with atypical cartilaginous tumors show a 10-year overall survival rate of 83%, patients with grade II tumors show 64% survival and patients with grade III chondrosarcomas show 29% 10-year survival rate.1,2 Dedifferentiated chondrosarcomas comprise 10% of all chondrosarcomas and are characterized by a high-grade dedifferentiated component juxtaposed to a low-grade cartilaginous component. (csfshayna.org)
  • Of all chondrogenic tumors, 28.5% are osteochondroma, 29.1% enchondroma, 21.7% conventional chondrosarcoma grade I-III, less than 5% are subungual exostosis and bizarre parosteal osteochondromatous proliferation combined, and the least common is mesenchymal chondrosarcoma at less than 1%, as reported by the WHO in 2020. (mdwiki.org)
  • A malignant mesenchymal tumor for which a distinct line of differentiation cannot be determined. (fpnotebook.com)
  • Chondrosarcoma is the second most frequent primary malignant tumor of bone, representing approximately 20-25% of all primary osseous neoplasms. (medscape.com)
  • Chondrosarcomas are intrinsically resistant to conventional chemo- and radiotherapy, and therefore surgical removal of the tumor is the only curative treatment option. (csfshayna.org)
  • In the latest version of the guidelines released in November 2020, surgery is the main treatment for chondrosarcoma, chordoma, and giant cell tumor of bone, which can be combined with radiotherapy or targeted therapy. (bvsalud.org)
  • Phase study of the tumor mutational burdenTtmb mutant IDH1 inhibitor ivosidenib: Safety and clinical activity in patients with advanced chondrosarcoma. (bvsalud.org)
  • [1] Distinguishing a large non-cancerous cartilage tumor, such as an enchondroma, from a chondrosarcoma grade I or atypical cartilaginous tumour is difficult. (mdwiki.org)
  • Although dedifferentiation in a chondrosarcoma was strongly considered, the pattern was considered unusual and the possibility of a collision tumor (enchondroma with desmoplastic fibroma) was also entertained, with recommended treatment to achieve control of a locally aggressive neoplasm. (biomedscis.com)
  • Imaging studies and biopsy help you to confirm your diagnosis on chondrosarcoma. (alwaysayurveda.net)
  • Final diagnosis was based on histological examination, which confirmed the hypothesis of low-grade parafalcine chondrosarcoma. (neoplasiaresearch.com)
  • A differential diagnosis of chondrosarcoma should be considered because of the life-threatening features of chondrosarcoma. (bvsalud.org)
  • [1] Osteochondroma and enchondroma are the most common non-cancerous types, and conventional chondrosarcoma is the most common cancerous type. (mdwiki.org)
  • Types of Chondrosarcoma and the classification is based on their look under microscope. (alwaysayurveda.net)
  • Primary chondrosarcomas are divided into central, periosteal, and peripheral types. (medscape.com)
  • A grade 2 periosteal chondrosarcoma in the humeral shaft. (radiologykey.com)
  • Chondrosarcoma including spindle cell and myxoid chondrosarcoma: mesenchymal chondrosarcoma. (medigraphic.com)
  • The morphologic features are distinct from other sarcomas associated with NCOA2 gene fusions, including mesenchymal chondrosarcoma, congenital/infantile spindle cell rhabdomyosarcoma, and soft tissue angiofibroma. (elsevier.com)
  • The procedure was performed under image intensifier control and the histological picture of the specimen showed features of a dedifferentiated lowgrade chondrosarcoma with abrupt demarcation between a distinct cartilaginous component and a spindle cell component. (biomedscis.com)
  • In June 2016 I was diagnosed with a rare and now discovered incurable sarcoma cancer called Mesenchymal Chondrosarcoma. (theactiveamputee.org)
  • Dedifferentiation of a low-grade chondrosarcoma is thought to occur when a high-grade sarcoma develops within the locally aggressive lesion [1]. (biomedscis.com)
  • Benign cartilage lesions can be difficult to differentiate from slow-growing, low-grade chondrosarcomas. (medscape.com)
  • Secondary chondrosarcoma can occur in a previously benign cartilaginous lesion. (medscape.com)
  • Chondrosarcoma (Chs) is the third most frequent primary malignant tumour of bone and can be primary or secondary, the latter results mainly from the malignant transformation of a benign pre-existing tumour. (biomedcentral.com)
  • First described by Nora et al [ 1 ] in 1983, it is a rare, benign, reactive mineralizing mesenchymal lesion with less than 200 cases reported in the literature. (medscape.com)
  • Therefore, there is still an urgent need for novel therapeutic targets that can be easily and rapidly applied in the treatment of patients with high-grade metastatic or inoperable chondrosarcoma. (csfshayna.org)
  • IDH mutations are seen in 50% of chondrosarcomas, which represent approximately 25% of malignant bone neoplasms. (curesarcoma.org)
  • Less than 7% of chondrosarcomas occur in patients younger than 21 years. (medscape.com)
  • Preliminary data presented in this proposal demonstrates that IDH mutations impair the differentiation of untransformed mesenchymal progenitor cells by inhibiting the removal of a repressive chromatin mark (H3K9me2/me3) in genomic regions required for differentiation. (curesarcoma.org)
  • and 2) analyzing pre- and on-treatment samples of locally advanced IDH-mutant chondrosarcoma patients treated with an IDH1-mutant inhibitor to study the consequences of IDH1-mutant inhibition on transcription (RNA-seq), chromatin (ATAC-seq and ChIP-seq) and differentiation. (curesarcoma.org)
  • Differentiation of human mesenchymal stem cells in vitro resulted in induction of NFATp mRNA under chondrogenic conditions but not under conditions which initiate osteogenesis. (biomedcentral.com)
  • Using immunohistochemistry, nuclear as well as cytoplasmic survivin expression was analyzed in 207 chondrosarcomas of different subtypes. (csfshayna.org)
  • Secondary chondrosarcomas include clear cell, mesenchymal, and dedifferentiated chondrosarcomas. (medscape.com)
  • MRI is useful in evaluating the thickened cartilage cap in an osteochondroma in which a secondary chondrosarcoma develops. (medscape.com)
  • NCOA2 fusion that is distinct from mesenchymal chondrosarcoma. (bvsalud.org)
  • These tumours arise from either notochordal remnants or mesenchymal cells. (biomedcentral.com)
  • SC is a cartilaginous metaplasia of the mesenchymal remnants of the synovial tissue of the joints. (bvsalud.org)
  • Chondrosarcomas are known to be the third most common malignant tumour occurring in bone and constitutes approximately 20% of primary bone sarcomas [3]. (biomedscis.com)
  • Chondrosarcomas typically present in adults during the fifth to seventh decades and are rare in young patients. (medscape.com)
  • Chondrosarcoma is a cartilage forming tumour, typically found in flat bones such as the ilium. (biomedscis.com)
  • Dedifferentiated chondrosarcoma typically has 2 microscopic components, whereby the low-grade cartilaginous lesion is seen with a high grade sarcomatous component with an abrupt transition between the 2 zones [1]. (biomedscis.com)
  • Performing a truly representative biopsy of a chondrosarcoma is challenging because the lesion is composed of areas that carry different histologic grades. (medscape.com)
  • A rare aggressive variant of chondrosarcoma, characterized by a biphasic histologic pattern of small compact cells intermixed with islands of cartilaginous matrix. (bvsalud.org)
  • Even though surgery remains the mainstay of treatment for cerebral chondrosarcomas, adjuvant radiotherapy such as stereotactic, proton beam or carbon ion-beam therapy might be necessary in aggressive or incomplete removed cases. (neoplasiaresearch.com)
  • Kothary N, Law M, Cha S, Zagzag D. Conventional and Perfusion MR Imaging of Parafalcine Chondrosarcoma. (neoplasiaresearch.com)
  • A malignant mesenchymal neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones. (fpnotebook.com)
  • They can arise from mesenchymal tissue at any body site. (apollohospitals.com)
  • This study presents an analysis (efficacy and toxicity) of outcomes in patients with skull-base chordomas or chondrosarcomas treated with a fixed horizontal pencil proton beam. (biomedcentral.com)
  • Treatment with a fixed proton beam shows promising disease control and an acceptable toxicity rate, even the difficult-to-treat subpopulation of patients with skull-base chordomas or chondrosarcomas requiring dose escalation. (biomedcentral.com)
  • Chordomas and chondrosarcomas are rare among malignancies and mainly affect the skull base, sacrum bones, and vertebral column (less). (biomedcentral.com)
  • A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target. (3dhistech.com)
  • We report a case of a 38 year male with a large and poorly symptomatic parafalcine chondrosarcoma of the cranial vault which was removed en bloc. (neoplasiaresearch.com)
  • Ten-year survival of a rare malignancy called mesenchymal chondrosarcoma has been reported to be as low as 20 percent. (medworm.com)
  • Chordomas (CAs) and chondrosarcomas (CSAs) are rare tumours that are usually located near the base of the skull and very close to the brain's most critical structures. (biomedcentral.com)
  • Chondrosarcoma is a rare malignant tumour arising from the cartilage with a high variability in the clinicalcourse and overall prognosis. (neoplasiaresearch.com)
  • If the cap measures more than 1.5 cm in a skeletally mature patient, transformation to chondrosarcoma may have occurred. (medscape.com)
  • Coexistence of Extraskeletal Mesenchymal Chondrosarcoma and Isolated Hemihyperplasia: A Case Report. (docksci.com)
  • Coex stence of Extraskeletal Mesenchymal Chondrosarcoma and Isolated Hem hyperplas a: A Case Report Nihat Demirhan Demirkiran¹, Olcay Akdeniz¹, Onur Hapa¹, Hasan Havıtçıoğlu¹ What to Learn from this Article? (docksci.com)
  • Gunes M, Gunaldi O, Tugcu B, Tanriverdi O, Guler AK, Colluoglu B. Intracranial chondrosarcoma: a case report and review of the literature. (neoplasiaresearch.com)
  • Mesenchymal Chondrosarcoma of the Orbit: A case report and review of the literature. (jkos.org)
  • A malignant mesenchymal neoplasm arising exclusively from the soft tissues. (fpnotebook.com)